01—Abstract
Summary
Summary of the 8-K filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Bunge Global SA reported weaker third-quarter 2024 results, with GAAP diluted EPS of $1.56a versus $2.47 a year earlier and adjusted diluted EPS of $2.29 versus $2.99.
Net income attributable to Bunge fell to $221 millionb from $373 million, and net sales declined about 9% to $12.9 billion. Management attributed the decline to the current global margin environment. Core Segment EBIT dropped to $539 million from $711 million, with Agribusiness EBIT down to $322 million from $461 million.
Refined and Specialty Oils was solid but lower than last year, and Milling was pressured by high raw material costs in South America. Offsetting the weaker operating picture, Bunge completed the sale of its 50% stake in the BP Bunge Bioenergia sugar and bioenergy joint venture on October 1, 2024, and repurchased $200 millionc of shares in the quarter ($600 million year-to-date). Management now expects full-year 2024 adjusted EPS of at least $9.25, reflecting a stronger-than-expected Q3 in Agribusiness but a loss of income from the divested joint venture.
Cash generation weakened, with nine-month operating cash flow of $847 milliond versus $1,860 million and adjusted funds from operations of $1,283 million versus $1,935 million. Net debt rose during the period, and the pending Viterra combination continues to advance, with acquisition and integration costs of $62 million recorded in the quarter. For investors, the key trade-offs are a cyclically weaker earnings base and reduced cash flow against a diversified, globally scaled platform, active capital returns, and a pending transaction (Viterra) that management argues will add geographic and crop diversification.
The guidance floor implies a meaningful step-up in fourth-quarter adjusted EPS relative to Q3, so achieving it depends on continued margin and execution performance. Investors should also weigh the non-GAAP adjustments, which are substantial in the nine-month figures, particularly mark-to-market timing differences that management notes are expected to reverse over time.
02—Key points
Key Highlights
- Q3 2024 GAAP diluted EPS was $1.56, down from $2.47; adjusted diluted EPS was $2.29, down from $2.99. Nine-month GAAP EPS was $3.73 versus $10.71.
- Net sales fell to $12.9 billion from $14.2 billion, and gross profit declined to $772 million from $1,045 million.
- Core Segment EBIT was $539 million versus $711 million, with Agribusiness EBIT at $322 million (vs. $461 million) and Milling EBIT at $17 million (vs. $23 million).
- Sale of the 50% stake in BP Bunge Bioenergia closed October 1, 2024, removing the Sugar & Bioenergy segment's contribution (Q3 Non-core EBIT of $6 million vs. $55 million).
- Full-year 2024 adjusted EPS outlook is at least $9.25; adjusted effective tax rate expected at 22% to 24%, net interest expense $285 to $305 million, and capex at the upper end of $1.2 to $1.4 billion.
- Share repurchases totaled $200 million in Q3 and $600 million year-to-date, while nine-month operating cash flow fell to $847 million from $1,860 million and adjusted FFO fell to $1,283 million from $1,935 million.
- Viterra business combination remains pending with regulatory approvals in progress; Q3 acquisition and integration costs were $62 million, versus $47 million in the prior-year quarter.
03—Questions
Frequently Asked Questions
Why did Bunge's earnings decline in the third quarter of 2024?
Management attributed the decline to the current global margin environment. Agribusiness results were lower, with Merchandising and Processing both down year over year, although higher results in South America and Europe soy crush partly offset weakness in North America, Asia and European softseeds. Refined and Specialty Oils was lower in North and South America, and Milling was pressured by high raw material costs in South America.
What is the impact of selling the BP Bunge Bioenergia stake?
The sale of Bunge's 50% interest in the sugar and bioenergy joint venture closed on October 1, 2024. This removes that segment's earnings going forward, which is why management lowered the non-core outlook substantially. Non-core Segment EBIT was $6 million in Q3 2024 versus $55 million a year earlier, and management noted the lost income as a factor in the revised full-year guidance.
Is Bunge's full-year 2024 guidance still positive?
Management now expects full-year 2024 adjusted EPS of at least $9.25. This is below the prior-year level of $9.97 for the nine months alone and reflects weaker margins and the divestiture. The filing does not provide a GAAP EPS forecast because of the inability to quantify certain market-driven items, so investors should evaluate the adjusted figure alongside GAAP results.
How is Bunge's cash flow and balance sheet position?
Operating cash flow for the first nine months of 2024 was $847 million, compared with $1,860 million in 2023, mainly due to lower net income. Adjusted FFO was $1,283 million versus $1,935 million. Cash and equivalents rose to $2,836 million, but total debt increased, with long-term debt of $4,777 million and current portion of $663 million at September 30, 2024, versus $4,080 million and $5 million at year-end 2023. Management continued returning capital, repurchasing $600 million of shares year-to-date and paying $287 million in dividends.
What does the pending Viterra combination mean for investors?
Management says the combination will further diversify Bunge across geographies and crops and that integration planning is advancing, with progress toward remaining regulatory approvals. The company recorded $62 million of acquisition and integration costs in Q3 2024 and $185 million year-to-date, which reduced GAAP earnings but were excluded from adjusted EPS. Investors should monitor the timing of approvals and the size of ongoing integration costs.
04—Continue